| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 1632 |
| 1 | PREDNISONE | 1303 |
| 2 | DEXAMETHASONE | 1185 |
| 3 | DEXAMETHASONE 1.5 MG | 1185 |
| 4 | ACETAMINOPHEN | 851 |
| 5 | LENALIDOMIDE | 814 |
| 6 | TACROLIMUS | 742 |
| 7 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 734 |
| 8 | MYCOPHENOLATE MOFETIL | 733 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 698 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | REMDESIVIR | 505 | 0.0380 |
| 1 | OBINUTUZUMAB | 317 | 0.0187 |
| 2 | ERGOCALCIFEROL | 405 | 0.0136 |
| 3 | BENDAMUSTINE HCL | 181 | 0.0116 |
| 4 | OCRELIZUMAB | 678 | 0.0108 |
| 5 | HUMAN IMMUNOGLOBULIN G | 217 | 0.0104 |
| 6 | APIXABAN | 548 | 0.0081 |
| 7 | RITUXIMAB | 1632 | 0.0076 |
| 8 | TACROLIMUS OINTMENT 0.1% | 698 | 0.0055 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 698 | 0.0055 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 3414 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 2646 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1350 |
| 3 | Thalidomide Analog [EPC] | 1025 |
| 4 | Proton Pump Inhibitor [EPC] | 706 |
| 5 | Factor Xa Inhibitor [EPC] | 687 |
| 6 | Alkylating Drug [EPC] | 655 |
| 7 | Loop Diuretic [EPC] | 631 |
| 8 | Kinase Inhibitor [EPC] | 606 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 603 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 72 | 0.1047 |
| 1 | CD38-directed Cytolytic Antibody [EPC] | 399 | 0.0682 |
| 2 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 505 | 0.0380 |
| 3 | Guanylate Cyclase-C Agonist [EPC] | 32 | 0.0154 |
| 4 | CD19-directed Cytolytic Antibody [EPC] | 13 | 0.0152 |
| 5 | Provitamin D2 Compound [EPC] | 405 | 0.0136 |
| 6 | Human Immunoglobulin G [EPC] | 243 | 0.0115 |
| 7 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 43 | 0.0106 |
| 8 | Macrolide Antibacterial [EPC] | 9 | 0.0089 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 2646 | 0.0083 |